XL CDKN2C/CKS1B consists of a green-labeled probe hybridizing to the CDKN2C (p18) gene region at 1p32.3 and an orange-labeled probe hybridizing to the CKS1B gene region at 1q21-22.

Probe maps for selected products have been updated. These updates ensure a consistent presentation of all gaps larger than 10 kb including adjustments to markers, genes, and related elements. This update does not affect the device characteristics or product composition. Please refer to the list to find out which products now include updated probe maps.

Probe map details are based on UCSC Genome Browser GRCh37/hg19, with map components not to scale.

Multiple myeloma (MM) is a plasma cell malignancy characterized by very complex cytogenetic and molecular genetic aberrations. Hyperdiploid karyotypes are characterized mainly by trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, non-hyperdiploid karytoypes typically have translocations involving the IGH locus at 14q32. The most frequent deletions are 13q, 17p and 1p32.

Deletions of chromosome 1p have been described in 7-15% of cases of myeloma with inconsistent clinical consequences. CDKN2C at 1p32.3 has been identified in myeloma cell lines as the potential target of the deletion. Gain of 1q is one of the most recurrent chromosomal aberrations in MM. Amplification and overexpression of the CKS1B gene in chromosome band 1q21 has been associated with an aggressive clinical course in MM.

Clinical Applications

• Multiple Myeloma and Plasma Cell Neoplasms (MM)

XL CDKN2C/CKS1B hybridized to lymphocytes. Three normal interphases are shown.

• Hanamura et al (2006) Blood 108:1724-1732
• Leone et al (2008) Clin Cancer Res 14:6033-6041
• Jian et al (2016) Medicine 95:1-7